Showing 5081-5090 of 5771 results for "".
- European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10https://modernod.com/news/european-medicines-agency-grants-prime-access-to-proqrs-sepofarsen-for-lebers-congenital-amaurosis-10/2476779/ProQR Therapeutics announced that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 gene for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the Priority Medicines (PRIME) program by the European Med
- Pfizer to Combine Upjohn Off-Patent Drug Business With Mylan Into New Companyhttps://modernod.com/news/pfizer-to-combine-upjohn-off-patent-drug-business-with-mylan-into-new-company/2476776/Pfizer plans to combine its Upjohn off-patent branded and generic established medicines business with Mylan into a new company, the drugmakers announced Monday, confirming a recent report on the matter. Under the all-stock transaction, which has been unanimously approved by the boards of both com
- Hillrom Introduces Next-Generation Technology In Fight Against Diabetic Retinopathyhttps://modernod.com/news/hillrom-introduces-next-generation-technology-in-fight-against-diabetic-retinopathy/2476777/Hillrom announced its latest innovation in vision screening and diagnostics with the introduction of the Welch Allyn RetinaVue 700 Imager handheld retinal camera, which enables remote ophthalmologists to diagnose diabetic retinopathy during routine primary care office visits. “Our n
- Alcon Showcases New Vitrectomy Probe and Next Generation Ngenuity 3D Visualization System at ASRShttps://modernod.com/news/alcon-showcases-new-vitrectomy-probe-and-nextgeneration-ngenuity-3d-visualization-system-at-asrs/2476772/Alcon is introducing the Hypervit Dual Blade Vitrectomy Probe, the newest addition to the Constellation Vision System, at the American Society of Retina Specialists (ASRS) 2019 annual meeting taking place July 26-30 in Chicago. The company is also featuring its next generation Ngenuity 3D Visuali
- Aura Biosciences to Present Long-Term Clinical Data for AU-011 at ASRShttps://modernod.com/news/aura-biosciences-to-present-long-term-clinical-data-for-au-011-at-asrs/2476767/Aura Biosciences announced that 2-year clinical data from its ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the Am
- Omeros’ Omidria Receives Product-Specific J-Code from CMShttps://modernod.com/news/omeros-omidria-receives-product-specific-j-code-from-cms/2476766/Omeros announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3%. Omidria is
- Allegro Ophthalmics to Present Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at ASRShttps://modernod.com/news/allegro-ophthalmics-to-present-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-asrs/2476765/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD) will be presented during the Americ
- Bausch + Lomb Showcases New Retina Innovations at In-Booth Wet Lab at ASRShttps://modernod.com/news/bausch-lomb-showcases-new-retina-innovations-at-in-booth-wet-lab-at-asrs/2476764/Bausch + Lomb announced that it will showcase the company’s latest retina innovations, including the 23-gauge Bi-Blade dual port vitrectomy cutter and the FreeFlow infusion system, at a wet lab located in the Bausch + Lomb booth (#606) during the Annual Meeting of the American Society of Retina S
- Ocuphire Pharma Raises Over $5 Million to Complete Late Phase 2 Clinical Trials for Ophthalmic Disordershttps://modernod.com/news/ocuphire-pharma-raises-over-5-million-to-complete-late-phase-2-clinical-trials-for-ophthalmic-disorders/2476760/Ocuphire Pharma announced that it has closed on over $5 million of financing. Proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol. Nyxol is a novel eye drop treatment for multiple front-of-the-eye disorders, including night vision distur
- B+L Introduces FreeFlow Infusion System and 23-Gauge Bi-Blade Dual Port Vitrectomy Cutterhttps://modernod.com/news/bausch-lomb-introduces-freeflow-infusion-system-for-retina-surgery/2476761/Bausch + Lomb announced the launch of the FreeFlow infusion system for retina surgery and the 23-gauge Bi-Blade dual port vitrectomy cutter for the Stellaris Elite vision enhancement system. The FreeFlow infusion system allows for higher level of infusion flow compared to previous generati